Scarica l'app Stockscreener
9.06
1.57%
0.14
Dopo l'orario di chiusura:
9.06
Precedente Chiudi:
$8.92
Aprire:
$8.73
Volume 24 ore:
205.10K
Relative Volume:
0.68
Capitalizzazione di mercato:
$447.55M
Reddito:
-
Utile/perdita netta:
$-83.74M
Rapporto P/E:
-5.6273
EPS:
-1.61
Flusso di cassa netto:
$-64.98M
1 W Prestazione:
+7.47%
1M Prestazione:
-15.25%
6M Prestazione:
-68.06%
1 anno Prestazione:
-39.52%
Intervallo 1D:
$7.80
$9.11
Intervallo di 1 settimana:
$7.80
$9.11
Portata 52W:
$6.42
$29.60
Tyra Biosciences Inc Stock (TYRA) Company Profile
Nome
Tyra Biosciences Inc
Settore
Industria
Telefono
(619) 728-4760
Indirizzo
2656 STATE STREET, CARLSBAD
Confronta TYRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
TYRA
Tyra Biosciences Inc
|
9.06 | 447.55M | 0 | -83.74M | -64.98M | -1.61 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.52 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
561.49 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
595.70 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
232.75 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.22 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Tyra Biosciences Inc Stock (TYRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-01-07 | Iniziato | UBS | Buy |
| 2024-10-18 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2024-08-15 | Iniziato | Piper Sandler | Overweight |
| 2023-12-15 | Downgrade | BofA Securities | Buy → Neutral |
| 2023-06-30 | Iniziato | Wedbush | Outperform |
| 2023-02-03 | Iniziato | Oppenheimer | Outperform |
| 2022-06-23 | Iniziato | H.C. Wainwright | Buy |
| 2022-03-08 | Aggiornamento | Jefferies | Hold → Buy |
| 2021-11-08 | Downgrade | Jefferies | Buy → Hold |
| 2021-10-11 | Iniziato | BofA Securities | Buy |
| 2021-10-11 | Iniziato | Cowen | Outperform |
| 2021-10-11 | Iniziato | Jefferies | Buy |
Mostra tutto
Tyra Biosciences Inc Borsa (TYRA) Ultime notizie
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.83 Average PT from Brokerages - Defense World
(TYRA) Investment Analysis and Advice - news.stocktradersdaily.com
Vanguard Group Inc. Sells 37,643 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Wellington Management Group LLP Has $1.32 Million Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
American Century Companies Inc. Sells 20,857 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
KLP Kapitalforvaltning AS Buys New Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
TYRA INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces an Investigation into Tyra Biosciences Inc and Encourages Investors to Contact the Firm! - ACCESS Newswire
Advanced Urothelial Carcinoma Clinical Trials and Studies 2025: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - Barchart.com
Raymond James Financial Inc. Invests $761,000 in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
HC Wainwright Predicts Reduced Earnings for Tyra Biosciences - Defense World
Tyra Biosciences stock hits 52-week low at $8.14 - Investing.com Australia
Tyra Biosciences stock hits 52-week low at $8.14 By Investing.com - Investing.com South Africa
(TYRA) Technical Data - news.stocktradersdaily.com
Tyra Biosciences (NASDAQ:TYRA) Given Buy Rating at HC Wainwright - Defense World
H.C. Wainwright maintains $30 target on Tyra Biosciences stock By Investing.com - Investing.com Canada
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Sold by Swiss National Bank - Defense World
What is Wedbush’s Estimate for TYRA FY2029 Earnings? - Defense World
Tyra Biosciences Reports Fourth Quarter and Full Year 2024 Financial Results and Highlights - Citizen Tribune
Wedbush Reiterates “Outperform” Rating for Tyra Biosciences (NASDAQ:TYRA) - Defense World
Companies Like Tyra Biosciences (NASDAQ:TYRA) Are In A Position To Invest In Growth - Yahoo Finance
Charles Schwab Investment Management Inc. Trims Stock Position in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Biosciences (NASDAQ:TYRA) Shares Gap Up After Better-Than-Expected Earnings - Defense World
Tyra Biosciences Advances Precision Medicine Pipeline - TipRanks
Tyra Biosciences, Inc. (NASDAQ:TYRA) Shares Bought by Bank of New York Mellon Corp - Defense World
Tyra Biosciences stock hits 52-week low at $9.9 amid market challenges By Investing.com - Investing.com South Africa
Tyra Biosciences stock hits 52-week low at $9.9 amid market challenges - Investing.com
Tyra Biosciences, Inc. (NASDAQ:TYRA) Receives $30.50 Consensus Target Price from Analysts - Defense World
Trend Tracker for (TYRA) - news.stocktradersdaily.com
Victory Capital Management Inc. Purchases 26,560 Shares of Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Tyra Biosciences to Present at Oppenheimer's 34th Annual Healthc - GuruFocus.com
US Bancorp DE Purchases Shares of 3,612 Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
Incyte, Tesla And Other Big Stocks Moving Lower In Monday's Pre-Market Session - Benzinga India
Why Precision BioSciences Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket - NewsBreak: Local News & Alerts
Tyra Biosciences (NASDAQ:TYRA) Sees Large Volume Increase – Should You Buy? - Defense World
Tyra Biosciences Inc expected to post a loss of 48 cents a shareEarnings Preview - TradingView
(TYRA) On The My Stocks Page - Stock Traders Daily
Tyra Biosciences (TYRA) Expected to Announce Quarterly Earnings on Tuesday - Defense World
Tyra Biosciences stock hits 52-week low at $10.62 amid market challenges - Investing.com Australia
Tyra Biosciences stock hits 52-week low at $10.62 amid market challenges By Investing.com - Investing.com South Africa
Rhumbline Advisers Grows Stake in Tyra Biosciences, Inc. (NASDAQ:TYRA) - Defense World
BALVERSA Adoption on the Rise: Meeting Unmet Needs in Advanced Urothelial Cancer | DelveInsight - GlobeNewswire Inc.
Tyra Biosciences, Inc. (NASDAQ:TYRA) Sees Large Growth in Short Interest - Defense World
Advanced Urothelial Carcinoma Clinical Trial Pipeline - GlobeNewswire
Advanced Urothelial Carcinoma Clinical Trial Pipeline Analysis Demonstrates 20+ Key Companies at the Horizon Expected to Transform the Treatment Paradigm, Assesses DelveInsight - GlobeNewswire
Non-Muscle Invasive Bladder Cancer Clinical and Non-Clinical - openPR
(TYRA) Investment Report - Stock Traders Daily
Tyra Biosciences Inc Azioni (TYRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.15%
4.32%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):